Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.